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Abstract
Protein interacting with C-kinase 1 (PICK1) is a widely expressed scaffold protein known to interact via its
PSD-95/discs-large/ZO-1 (PDZ)-domain with several membrane proteins including the dopamine (DA) transporter
(DAT), the primary target for cocaine’s reinforcing actions. Here, we establish the importance of PICK1 for
behavioral effects observed after both acute and repeated administration of cocaine. In PICK1 knock-out (KO)
mice, the acute locomotor response to a single injection of cocaine was markedly attenuated. Moreover, in
support of a role for PICK1 in neuroadaptive changes induced by cocaine, we observed diminished cocaine intake
in a self-administration paradigm. Reduced behavioral effects of cocaine were not associated with decreased
striatal DAT distribution and most likely not caused by the 30% reduction in synaptosomal DA uptake observed
in PICK1 KO mice. The PICK1 KO mice demonstrated preserved behavioral responses to DA receptor agonists
supporting intact downstream DA receptor signaling. Unexpectedly, we found a prominent increase in striatal DA
content and levels of striatal tyrosine hydroxylase (TH) in PICK1 KO mice. Chronoamperometric recordings
showed enhanced DA release in PICK1 KO mice, consistent with increased striatal DA pools. Viral-mediated
knock-down (KD) of PICK1 in cultured dopaminergic neurons increased TH expression, supporting a direct
cellular effect of PICK1. In summary, in addition to demonstrating a key role of PICK1 in mediating behavioral
effects of cocaine, our data reveal a so far unappreciated role of PICK1 in DA homeostasis that possibly involves
negative regulation of striatal TH levels.
Significance Statement
Cocaine addiction is a major societal problem and better treatments are needed. We demonstrate here the
importance of the PSD-95/discs-large/ZO-1 (PDZ)-domain scaffold protein protein interacting with
C-kinase 1 (PICK1) for both the acute reinforcing effects of cocaine and the long-term behavioral changes
seen as a consequence of repeated cocaine exposure. Interestingly, our data suggest that these alterations
are independent of PICK1 binding to the primary target of cocaine, the dopamine transporter (DAT).
Moreover, our study reveals a novel role of PICK1 in maintenance of DA homeostasis that involves negative
regulation of the levels of striatal tyrosine hydroxylase (TH), the rate-limiting enzyme in DA synthesis.
Summarized, these data provide an important framework for further exploring the role of PICK1 in addiction
and as putative target for treatment of psychostimulant abuse.
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Introduction
Cocaine is a highly addictive and widely abused psy-
chostimulant (Karila et al., 2012; Proctor, 2012; Degen-
hardt et al., 2013; Karila et al., 2014). Treatment of cocaine
abuse, however, remains a major challenge and still no
pharmacological agents have proven therapeutically use-
ful (Kristensen et al., 2011; Shorter et al., 2015). The
reinforcing properties of cocaine can be attributed primar-
ily to its high-affinity interaction with the presynaptic
plasma membrane dopamine (DA) transporter (DAT). DAT
mediates rapid reuptake of DA from the extracellular
space (Giros et al., 1996; Kristensen et al., 2011) and is
thereby critical for replenishment of intracellular striatal
DA pools (Jones et al., 1998). Binding of cocaine to DAT
leads to a fast increase in extracellular DA, stimulation of
DA receptors and subsequent long-lasting changes in
synaptic plasticity, which are thought to underlie the crav-
ing for continuous drug intake (Chen et al., 2006; Thom-
sen et al., 2009).
Protein interacting with C-kinase 1 (PICK1) is a scaffold
protein implicated in several cellular functions (Xu and Xia,
2006; Hanley, 2008; Focant and Hermans, 2013). Scaffold
proteins constitute a highly diverse family of proteins that
serve a key role in orchestrating neuronal signaling pro-
cesses ensuring specificity in intracellular signaling net-
works (Kim and Sheng, 2004; Good et al., 2011). PICK1 is
unique by possessing both a PSD-95/discs-large/ZO-1
(PDZ) protein interaction domain and a lipid binding BAR
(Bin/amphiphysin/Rvs) domain (Hanley, 2008; Madsen
et al., 2012). The BAR-domain is dimeric and thus PICK1
contains in its functional form two separate PDZ-domains
allowing simultaneous binding of two interaction partners
(Xu and Xia, 2006; Hanley, 2008; Focant and Hermans,
2013). The PDZ-domain of PICK1 interacts with the C
termini of several receptors, channels and transporters
expressed in the CNS (Xia et al., 1999; Dev et al., 2000;
Torres et al., 2001; Madsen et al., 2005). These include
DAT (Torres et al., 2001; Bjerggaard et al., 2004) and the
AMPA receptor (AMPAR) subunit ionotropic glutamate
receptor 2 (GluA2; Xia et al., 2000; Kim et al., 2001; Jin
et al., 2006; Steinberg et al., 2006; Thorsen et al., 2010),
and for both, it has been suggested that PICK1 modulates
their trafficking (Xia et al., 2000; Kim et al., 2001; Torres
et al., 2001; Jin et al., 2006; Steinberg et al., 2006;
Thorsen et al., 2010). Interfering with the interaction be-
tween PICK1 and AMPA receptors has previously been
shown to blunt the synaptic plasticity induced at gluta-
matergic synapses onto ventral tegmental area (VTA) do-
paminergic neurons on a single cocaine exposure
(Bellone and Lüscher, 2006). Moreover, both cerebellar
and hippocampal long-term depression is abolished on
disruption of the PICK1-GluA2 interaction (Xia et al., 2000;
Kim et al., 2001; Jin et al., 2006; Steinberg et al., 2006;
Thorsen et al., 2010). However, the consequences of
disrupting PICK1-DAT interactions for the behavioral ef-
fects of cocaine are unknown.
Here, we investigate the importance of PICK1 for the
behavioral actions of cocaine. In mice with targeted de-
letion of PICK1 [PICK1 knock-out (KO) mice], the acute
locomotor response to a single injection of cocaine was
markedly attenuated. Moreover, cocaine intake was
diminished in a self-administration paradigm. These be-
havioral changes were not associated with altered pre-
synaptic DAT expression or aberrant postsynaptic DA
receptor activation. Intriguingly, we found that PICK1 KO
mice displayed increased striatal levels of tyrosine hy-
droxylase (TH) and DA, relative to wild-type littermates.
Chronoamperometric recordings in striatum revealed en-
hanced DA release in PICK1 KO mice further supporting
increased striatal DA pools. The importance of PICK1
specifically in DA neurons was confirmed by lentiviral
knock-down (KD) of PICK1 in cultured midbrain dopami-
nergic neurons resulting in elevated TH expression. How-
ever, neither coimmunoprecipitation nor fluorescence
polarization experiments showed a direct interaction be-
tween TH and PICK1. Our data demonstrate the impor-
tance of PICK1 for regulating behavioral effects of
cocaine, and reveal a so far unknown role of PICK1 in
maintenance of DA homeostasis.
Materials and Methods
Subjects
Male PICK1 KO mice (Gardner et al., 2005), DAT  Ala
knock-in mice (Rickhag et al., 2013) and wild-type litter-
mates of at least 10 weeks of age at the beginning of an
experiment were used, unless otherwise specified. Mice
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were group-housed in a temperature-controlled room
maintained on a 12/12 h light/dark cycle (lights on at 7
A.M.) with access to standard rodent chow and water ad
libitum. Animals were allowed to habituate to the facility
for at least 7 d before initiation of experiments. Animal
experiments were performed in accordance with the
guidelines of the Danish Animal Experimentation Inspec-
torate (permission number 2012-15-293-00279 and 2012-
15-2934-00038) in a fully AAALAC (American Association
for Laboratory Animal Care)-accredited facility under the
supervision of a local animal welfare committee. Chrono-
amperometric experiments conducted at University of
Texas Health Science Center at San Antonio were per-
formed in accordance with Institutional Animal Care and
Use Committee approved protocols, in a fully AAALAC-
accredited facility. All efforts were made to minimize pain
and discomfort as well as the number of animals used
during the experiments.
Drugs
SKF82958 hydrobromide and quinpirole hydrochloride
was purchased from Sigma-Aldrich. Cocaine hydrochloride
was obtained from the Copenhagen University Hospital
Pharmacy. All drugs were prepared in 0.9% aqueous NaCl,
with a final pH 6–7 and injected intraperitoneally in a volume
of 10 ml/kg.
Drug-induced hyperlocomotion without habituation
Locomotor activity was measured in activity boxes as
previously described (Sørensen et al., 2012; Rickhag
et al., 2013). Mice (wild-type/PICK1 KO/DAT  Ala mice)
were injected with either 0-, 5-, 10-, or 30-mg/kg cocaine
dissolved in saline intraperitoneally 3–7 min before test-
ing. The animals were then placed in a cage and the
activity was measured for 1 h. Each mouse only received
one dose of cocaine and cages were cleaned between
tests.
Drug-induced hyperlocomotion with habituation
PICK1 KO and wild-type mice were habituated to the
experimental room for a minimum of 30 min before the
experiment. The mice were placed in the open field (40 
40  80 cm) for a 120-min habituation period followed by
intraperitoneal administration of the DA D1 receptor (D1R)
agonist, SKF82958 (0.3 or 1 mg/kg), cocaine (10 or 30
mg/kg), DA D2 receptor (D2R) agonist, quinpirole (0.1 or
10 mg/kg), or vehicle. With a minimum 7-d washout pe-
riod, mice were retested in a counterbalanced Latin-
square design so that each animal only received the same
drug once. A video camera placed above the open field
recorded the animals’ behavior and the distance traveled
by the animal was analyzed using the video-tracking soft-
ware EthoVision (Noldus). For best possible comparison
to the effect of cocaine on the unhabituated mice, loco-
motion was analyzed for the 60 min before and after drug
injection (injection at t  120).
Cocaine-induced locomotor sensitization
After administration of saline on the initial day (day 0),
PICK1 KO and wild-type mice were divided into two
groups that received either cocaine (10 mg/kg, i.p.) or
saline for 6 d (day 1–6). All mice were given cocaine (10
mg/kg, i.p.) on day 12 and day 20 and retested in the open
field. On day 21, all mice were injected with saline and
re-exposed to the open field to examine whether context
conditioning had any effect on the observed response.
Mice spent 60 min in the open field box on all testing days,
and locomotion was recorded and analyzed using Etho-
Vision (Noldus).
Intravenous self-administration of cocaine or liquid
food
Equipment, training, and evaluation procedures were
performed as previously described for chronic self-
administration of cocaine or liquid food (Schmidt et al.,
2011; Sørensen et al., 2015).
Cocaine (1.0 mg/kg per infusion) was available under a
fixed ratio 1:1 (FR1) schedule in daily 3-h sessions, 5–6 d
per week, until baseline criteria was met (20 reinforcers
earned, with 20% variation over two consecutive ses-
sions and 70% responses in the active hole). In consec-
utive sessions, saline was substituted for cocaine until
extinction criteria were met (80% of the baseline re-
sponding for cocaine self-administration). This was fol-
lowed by reintroduction of the training dose until
previously established baseline criteria were met again or
a new baseline was established with similar requirements
as above. Subsequently, dose-effect functions (saline,
0.03, 0.1, 0.3, 1.0 mg/kg per infusion of cocaine) were
determined for each mouse according to a Latin-square
design twice in each mouse. To prevent overdosing, total
drug intake was limited to 30 mg/kg per session.
Another set of experimentally naïve mice was used for
self-administration of a nondrug reinforcer under a FR1
schedule. The mice were food deprived for 18–20 h (with
ad libitum water) before the first presentation of liquid
food (5 ml of Nutridrink, vanilla flavor, Nutricia) in the
operant chamber. When 1.5 ml of the 5 ml available was
consumed per 2-h session, mice were placed in the
operant chamber with one active and one inactive
nose-poke hole for daily 2-h sessions similar to cocaine
FR1 self-administration. Acquisition lasted until criteria
were met (20 reinforcers earned, with 20% variation
over two consecutive sessions and 70% responses in
the active hole). Subsequently, water was substituted
until responding was extinguished to 80% of food-
maintained responding. This was followed by reintro-
duction of the training concentration of liquid food until
previously established baseline criteria were met again
or a new baseline was established with similar require-
ments as above. Then, a range of liquid food dilutions
(Nutridrink: water; 3%, 10%, 32%, and 100%) was
presented according to a Latin-square design, deter-
mined twice in each mouse.
Immunoblotting
Equal amounts of samples, prepared as described in
the following sections, were run on a 10/15 well any kDa,
prestacked gel (Bio-Rad) and transferred to PVDF mem-
branes (Millipore). Membranes were blocked in either 5%
bovine serum albumin in 0.05% PBS/Tween 20 or 2%
PVP-40 in 0.05% PBS/Tween 20 (phospho-proteins) or in
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5% dry milk in 0.05% PBS/Tween 20 (unphoshorylated
proteins), and incubated overnight with antibodies against
flotillin (1:1000, SAB2500404, rabbit polyclonal, Sigma),
DAT (1:1000, MAB369, rat monoclonal, Millipore), D1R
(1:1000, D2944, rat polyclonal, Sigma), TH (1:1000,
MAB318, mouse monoclonal, Millipore), phospho-TH (1:
1000, 2791S, rabbit polyclonal, Cell Signaling), cAMP
response element binding protein (CREB; 1:1000, 48H2,
rabbit polyclonal, Cell Signaling), anti-phospho-Ser133
CREB (1:1000, p1010-133, PhospoSolutions), or vesicular
monoamine transporter-2 (VMAT2; 1:1000, Ab191121,
rabbit polyclonal, Abcam) depending on the experiment.
Following incubation with horseradish peroxidase (HRP)-
conjugated anti-rabbit/anti-mouse/anti-rat antibodies (1:
2000), the blots were visualized by chemiluminescence
(ECL kit, GE Healthcare for un-phosphorylated proteins
and SuperSignal ELISA Femto Maximum Sensitivity Sub-
strate, Thermo Scientific for phosphorylated proteins) us-
ing AlphaEase (Alpha Innotech). To verify equal protein
loading, the membranes were probed with antibodies
against Na/K ATPase (1:1000, Ab7671, mouse mono-
clonal, Abcam) or HRP-conjugated -actin (1:10000,
A3854, mouse monoclonal, Sigma). In surface biotinyla-
tion experiments, band intensities of biotinylated DAT and
D1R were normalized to the band intensity of total DAT
and D1R in the respective input lysates.
Preparation of striatal lysates for surface
biotinylation experiments
Surface biotinylation was performed as previously de-
scribed (Runegaard et al., 2017).
Preparation of striatal and midbrain lysates for
immunoblotting
Adult mice were killed by decapitation and brains rap-
idly removed. Striatum and midbrain were rapidly dis-
sected and homogenized in RIPA lysis buffer (1% Triton
X-100, 1 mM EGTA, 1 mM EDTA, 150 mM NaCl, 1%
NP-40, 10 mM TRIS-HCl; pH 7.4) supplemented with
protease inhibitor cocktail (Roche Diagnostics) and phos-
phatase inhibitor cocktail 3 (Sigma Aldrich). Tissue was
incubated on ice for 20 min followed by centrifugation at
16,000 g for 20 min at 4°C. Supernatant was transferred
to new tubes and an aliquot was removed to determine
protein concentration using a BCA Protein Assay kit
(Pierce). Samples were eluted in SDS loading buffer and
left at 37°C for 30 min followed by immunoblotting.
Preparation of striatal lysates for sucrose gradient
centrifugation experiments
Adult mice were killed by decapitation and brains rap-
idly removed. Striatum from PICK1 wild-type and KO mice
were rapidly dissected and homogenized in homogeniza-
tion buffer (0.32 M sucrose and 4 mM HEPES; pH 7.4).
Samples were centrifuged at 1000  g for 10 min at 4°C
to remove cell nuclei followed by centrifugation at 16,000
 g for 20 min at 4°C to pellet the membranes. The pellet
was homogenized in 1-ml lysis buffer [1% Brij56 (w/V)],
protease inhibitor, and 0.2 mM PMSF in the gradient
buffer (25 mM HEPES and 150 mM NaCl; pH 7.4) for 15
min on ice. A 1-ml sample was mixed with 1-ml sucrose
(80% w/V) in gradient buffer to create 2 ml with final 40%
(w/V) sucrose content in a 15-ml centrifuge tube (Beck-
man Coulter). On top of this, a 12 ml 35–15% continuous
gradient was assembled using a SG15 gradient maker
(Hoefer). Subsequently the gradient was ultracentrifuged
at 100,000  g for 18 h in a Beckman SW28.1 rotor head
(Beckman Coulter) and fractionated into nine fractions
using a P1 pump. Each fraction was incubated for 30 min
at 37°C in SDS loading buffer with a final concentration of
66 mM DTT followed by immunoblotting.
Preparation of striatal and midbrain lysates for
coimmunoprecipitation experiments
Adult male C57BL/6 mice (age, two to three months)
were killed and brains immediately placed in ice-cold
artificial CSF (aCSF; 124 mM NaCl, 3 mM KCl, 26 mM
NaHCO3, 1.25 mM NaH2PO4, 2 mM CaCl2, 1 mM MgSO4,
and 10 mM D-glucose) while striatum and midbrain were
dissected. Tissue was homogenized in lysis buffer [50 mM
Tris (pH 7.4), 150 mM NaCl, 0.1% SDS, 0.5% Na deoxy-
cholate, 1% Triton X-100, 5 mM NaF, and 1 Roche
protease inhibitor cocktail]. Lysates were centrifuged at
20,000  g for 15 min and supernatants precleared with
streptavidin beads (Dynabeads MyOne Streptavidin T1,
Thermo). A total of 500-g protein lysate was incubated
with 5-g TH/PICK1 Ab (TH, MAB318 Millipore; PICK1
rabbit, a kind gift from Dr. Richard Huganir, Johns Hop-
kins University, Baltimore, MD) and incubated at 4°C,
rotating overnight. Protein-G beads were added and sam-
ples left for an additional 3 h. Beads were washed in lysis
buffer and proteins were eluted in SDS loading buffer and
left at 100°C for 6 min followed by immunoblotting.
Striatal DA uptake
Synaptosomal uptake assay was performed as de-
scribed previously (Jensen et al., 2017; Runegaard et al.,
2017).
HPLC determination of striatal DA content
HPLC analysis was performed as described previously
(Jensen et al., 2017).
In vivo high-speed chronoamperometry
In vivo high-speed chronoamperometry was conducted
using the FAST-12 system (Quanteon; http://www.quanteon.
cc) as previously described (Owens et al., 2005; Williams
et al., 2007; Daws et al., 2016) with some modification.
Recording electrode/micropipette assemblies were con-
structed using a single carbon-fiber (30 m in diameter;
Specialty Materials), which was sealed inside fused silica
tubing (SCHOTT North America). The exposed tip of the
carbon fiber (150 m in length) was coated with 5%
Nafion (Aldrich Chemical Co; three to four coats baked at
200°C for 5 min per coat) to provide a 1000-fold selectivity
of DA over its metabolite 3,4-dihydroxyphenylacetic acid
(DOPAC). Under these conditions, microelectrodes display
linear amperometric responses to 0.25–10 M DA during in
vitro calibration in 100 mM PBS (pH 7.4).
Male wild-type or PICK1 KO mice weighing 26–36 g
were anesthetized by intraperitoneal injection (10-ml/kg
body weight) of a mixture of urethane (70 mg/ml) and
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-chloralose (7 mg/ml), then fitted with an endotracheal
tube to facilitate breathing, and placed into a stereotaxic
frame (David Kopf Instruments). Body temperature was
maintained by placing the animals on a water-circulated
heating pad. To locally deliver potassium chloride (KCl;
200 M, Sigma, pH 7.4) close to the recording site, a
glass multi-barrel micropipette (FHC) was positioned ad-
jacent to the microelectrode using sticky wax (Moyco).
The center-to-center distance between the microelec-
trode and the micropipette ejector was 200 m. The
electrode/micropipette assembly was lowered into the
striatum at the following coordinates (in mm from bregma;
Franklin, 1997): A/P, 1.1; M/L, 1.4; and D/V, 2.25. To
evoke release of endogenous DA, KCl was pressure-
ejected using a Picospritzer II (General Valve Corporation)
in an ejection volume 43  7 nl, 8.5  1 pmol and 41  6
nl, 8.0  1 pmol, for wild type and KO, respectively. To
record KCl-evoked efflux of DA at the carbon fiber elec-
trode, oxidation potentials consisting of 100-ms pulses of
550 mV, each separated by a 900-ms interval, during
which the resting potential was maintained at 0 mV, were
applied with respect to an Ag/AgCl reference electrode
implanted into the contralateral superficial cortex. Oxida-
tion and reduction currents were digitally integrated dur-
ing the last 80 ms of each 100-ms voltage pulse. For each
recording session, DA was identified by its reduction/
oxidation current ratio, which ranged from 0.50 to 0.83.
Detailed methods can be found in Daws et al. (2016). Peak
signal amplitude was used as an index of striatal tissue
pools of DA. At the conclusion of each experiment, an
electrolytic lesion was made to mark the placement of the
recording electrode tip. Mice were then decapitated while
still anesthetized, and their brains were removed, frozen
on dry ice, and stored at 80°C until sectioned (20 m)
for histologic verification of electrode location within the
striatum.
Isolation and mRNA expression analysis
Adult mice were killed by decapitation and brains rap-
idly removed. Midbrain from PICK1 wild-type and KO
mice was rapidly dissected in the presence of RNase
away (Molecular Bioproducts, Fischer scientific). Samples
were collected on dry ice and placed at -80˚C until RNA
extraction. Samples were lyzed using a QIAGEN mi-
croRNA column (QIAGEN) according to the manufactur-
er’s instructions, including DNase treatment. Conversion
from RNA to cDNA was done with SuperScript III (Thermo
Fisher). Reaction 1 (70°C for 5 min): max 1-g RNA, 50-ng
random primer, 0.2 mol DTT, H2O to a final volume 15 l.
Reaction 2 (10 min at 25°C, 50 min at 50°C, and 5 min at
80°C): 10 reverse transcription buffer, 10 nmol dNTP
mix, 40-U RNaseOUT, 200-U superscript, H2O to a final
volume of 5 l, thereafter added to reaction 1. Before
running qPCR on the samples, cDNA was diluted 10
with sterile water. The Agilent Mx3000p (Agilent Technol-
ogies) real-time thermocycler was used to perform the
qPCR using SYBR green (PrecisionPLus 2 qPCR Mas-
termix Primer design Ltd.) as probe. Data collection was
performed by MxPro software and analyzed in Microsoft
Excel as well as GraphPad Prism version 6. All samples
were run in duplicates and -actin was used as reference/
housekeeping gene. Relative expression was calculated
through the 		Cq method (Pfaffl, 2001). Primers for
-actin forward: TTCTACAATGAGCTGCGTGTG and re-
verse: GGGGTGTTGAAGGTCTCAAA; TH forward: CCG
TCATGCCTCCTCACCTATG and reverse: CCTGGGAGA
ACTGGGCAAATG.
Protein expression, purification, and fluorescence
polarization assay
Escherichia coli transformed with a PICK1 encoding
plasmid (pET41; Madsen et al., 2005) were inoculated
overnight in 50 ml of lysogeny broth media (kanamycin),
diluted into 1-l lysogeny broth media (kanamycin) and
grown at 37°C to OD 0.6. Protein expression was induced
with 0.5 mM IPTG and grown overnight at 20°C. Cells
were harvested and resuspended in lysis buffer contain-
ing 50 mM Tris, 125 mM NaCl, 2 mM DTT (Sigma), 1%
Triton X-100 (Sigma), 20-g/ml DNase 1, and cOmplete
protease inhibitor cocktail (Roche). Lysate was frozen at
-80°C to induce cell lysis. The bacterial suspension was
thawed and cleared by centrifugation (F20 rotor, 36,000
g for 30 min at 4°C). Supernatant was incubated with
glutathione-sepharose 4B beads (GE Healthcare) for 2 h
at 4°C under gentle rotation. The beads were pelleted at
4000  g for 5 min and washed twice in 50 mM Tris, 125
mM NaCl, 2 mM DTT, and 0.01% Triton X-100. Beads
were transferred to a PD10 gravity column and were
washed three times. Protein was separated from GST by
thrombin (Millipore) incubation overnight at 4°C with gen-
tle rotation. PICK1 was eluted on ice and absorption at
280 nm was measured on a TECAN plate reader, followed
by protein concentration calculations using lambert beers
law (A  cl), A280PICK1  32320(cmmol/l)-1. A pep-
tide of the 11 most C-terminal residues of mouse TH
(HTLTQALSAIS) was ordered from TAGcopenhagen A/S
with 
95% purity. The peptide was dissolved in 10%
DMSO and wash buffer to a concentration of 2 mM, and
a final assay max concentration of 1 mM was used. The
fluorescence polarization assay was performed as previ-
ously described (Madsen et al., 2005; Erlendsson et al.,
2014) with a fixed concentration of PICK1 (1 M, nonsatu-
rated) and fluorescent tracer (Oregon-Green DATC13, 20
nM), preincubated for 15 min after which increasing con-
centrations of unlabeled TH-C11 peptide were added and
incubated for 20 min on ice in a black 190-l nonbinding
surface 96-well plate (Corning). Fluorescence polarization
was measured on an Omega POLARstar plate reader,
488-nm excitation and 535-nm emission.
Confocal microscopy
Confocal microscopy was performed using a Zeiss
LSM 510 confocal laser-scanning microscope with an oil
immersion 63  1.4 numerical aperture objective (Carl
Zeiss). Alexa Fluor 488 dye was excited with a 488-nm
laserline from an argon-krypton laser and emitted light
detected using a 505- to 530-nm bandpass filter. Alexa
Fluor 568 dye was excited with a 543-nm helium-neon
laser, and fluorescence was recorded using a 560-nm
long-pass filter. Images were analyzed with ImageJ (FIJI)
software.
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Immunohistochemistry of perfused brain sections for
confocal microscopy
Adult mice were anaesthetized and transcardially per-
fused with 4% paraformaldehyde in 0.1 M PBS. Coronal
midbrain sections (40 m) were used for fluorescence
immunohistochemistry. Initially, antigen retrieval was per-
formed by treatment with 10 mM sodium citrate buffer (pH
6.0) for 30 min at 80°C. Brain sections were then rinsed in
PBS and preincubated in PBS containing 5% goat serum,
1% bovine serum albumin and 0.3% Triton X-100 for 1 h.
Sections were subsequently incubated with a custom
generated mouse monoclonal PICK1 antibody (1:1000,
2G10; described in Jansen et al., 2009) and rabbit poly-
clonal TH (1:1000, OPA-04050, Affinity Bioreagents) at
4°C overnight. Sections were rinsed in washing buffer
(0.25% BSA, 0.1% Triton X-100 in PBS) and then incu-
bated with biotinylated goat anti-mouse (1:400, E0433,
DAKO Cytomation A/S) or Alexa Fluor 568 goat anti-rabbit
IgG (1:1000, A11036, Invitrogen). Following rinsing, slices
were incubated with avidin-biotin-peroxidase complex
(Vector Laboratories), rinsed, and incubated with biotinyl
tyramide amplification reagent (PerkinElmer) and incu-
bated with streptavidin-conjugated Alexa Fluor 488 (1:
400, S11223, Thermo Fisher Scientific) to detect PICK1.
Additional rinsing was followed by mounting on Super-
Frost slides (Menzel-Gläser, Braunschweig, Germany)
and cover-slipping using Prolong Gold antifade reagent
(Invitrogen).
Culturing, transduction, and immunocytochemistry
of dopaminergic neurons for confocal microscopy
Dopaminergic neurons were isolated from ventral mid-
brain tissue dissected from 1- to 3-d-old rat pups and
plated on a monolayer of glia cells on coverslips using a
protocol modified from (Rayport et al., 1992) as described
in (Eriksen et al., 2009). For lentiviral transduction of the
neurons, vectors were driven by the dual promoter FUGW
with the H1 promoter driving the expression of the small
hairpin (ShPICK1) targeting the PICK1 sequence (CTAT-
GAGTACCGCCTTATCCT) and the ubiquitin promoter
driving the expression of GFP (PICK1 KD; Citri et al.,
2010). In the control vector (GFP), the sequence of the
ShPICK1 was removed before the PCR product of the
deleted ShPICK1 fragment and the PICK1 KD vector was
digested and ligated together using AfeI and BamHI. Re-
moval of ShPICK1 was achieved by synthesis of a 500 bp
PCR fragment using the primers AGTAACGGATC-
CTTTTTCTAGCCCCAAGGGCG and TCGCCGAGAAG-
GGACTACTTTTCCTCGCCTG and the original PICK1 KD
construct as template. Consequently, the control GFP
vector only drives the expression of GFP under the ubiq-
uitin promoter. Verification of both constructs was per-
formed by dideoxynucleotide sequencing (Eurofins
Genomics, Ebersberg, Germany). Transduction of dopa-
minergic neurons was initiated the first day after plating
dopaminergic neurons on the monolayer of glia cells.
Before transduction, half the medium was removed from
each well and kept in incubator. Equal amounts of virus
inducing expression of either PICK1 KD or GFP were
added below the medium surface in two to three spots.
After 6–8 h, the media was transferred back to the dopa-
minergic neurons and 5-fluorodeoxyuridine was added to
the medium to inhibit cell growth. For immunocytochem-
istry, dopaminergic neurons were washed followed by
15-min fixation in 4% paraformaldehyde. Cells were
washed followed by 20 min in permeabilization  block-
ing buffer (0.2% saponin  5% goat serum in PBS).
Neurons were stained with a rabbit anti-TH antibody (1:
1000, OPA1-04050, Thermo Fischer Scientific) and a
mouse anti-PICK1 antibody (2G10; described in (Jansen
et al., 2009), 1:1000) for 1 h at room temperature. Cells
were washed in blocking buffer and incubated for 45 min
with Alexa Fluor 568 goat anti-rabbit and Alexa Fluor 647
goat anti-mouse (both 1:500, Life Technologies).
Statistical analysis
The dataset was examined for normality (Shapiro–Wilk
and Kolmogorov–Smirnov normality test), outliers were
removed by Grubbs outlier analysis, and all data are
presented as mean  SEM. Significance level was set to
p  0.05. GraphPad Prism was used for data analyses
except for three-way ANOVAs, which were analyzed in
SPSS. All statistical analysis run are reported in detail in
Table 1.
Data were compared between groups using unpaired t
tests when a Gaussian distribution was observed. Other-
wise, the unparametric Mann–Whitney test was used.
When comparing two normalized groups, with wild type
set to 1 (Western blotting), one-sample t test was used.
For cocaine administration without habituation of animals,
as well as the self-administration paradigm, we used a
two-way ANOVA with genotype and dose as factors. F
values are reported as F (degrees of freedom between
groups, degrees of freedom within groups). Pairwise
multiple comparison procedures were made using the
Holm–Sidak method. For drug-induced locomotion with
habituation of animals as well as the sensitization para-
digm, we instead used a three-way ANOVA with geno-
type, injection (before vs after drug) and dose as factors.
Results
Attenuated locomotor response to cocaine in mice
with deletion of PICK1
To investigate a possible role of PICK1 in mediating the
behavioral actions of cocaine, we assessed cocaine-
induced hyperactivity in PICK1 KO mice and littermate
wild-type controls (Fig. 1). Mice were injected with 0-, 5-,
10-, or 30-mg/kg cocaine and placed directly in activity
boxes for 1 h. Analysis of their locomotion revealed an
overall treatment effect of cocaine with a significant differ-
ence between genotypes (FGENOTYPE(1,87)  14.91, p 
0.0002, FTREATMENT(3,87)  17.5, p  0.0001, FINTERAC-
TION(3,87)  1.88, p  0.32; Fig. 1A). Further statistical
assessment of the genotype effect revealed a significantly
attenuated cocaine-induced behavioral response in the
PICK1 KO mice after injection of both 10- and 30-mg/kg
cocaine (saline; t(87)  0.76, p  0.45, 5 mg/kg; t(87) 
1.32, p  0.342, 10 mg/kg; t(87)  2.59, p  0.033, 30
mg/kg; t(87)  2.97, p  0.015; Fig. 1A). Wild-type mice
responded in a dose-dependent manner to 5-, 10-, and
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test Sample size Statistical data
1A
Cocaine administration in activity
boxes with no habituation
(PICK1 KO and WT mice)













p  0.32, F(3,87)  1.88
Treatment:
p  0.0001, F(3,87)  17.5
Genotype:
p  0.0002, F(1,87)  14.91
Multiple comparison, Treatment, df  87:
WT (compared to saline):
5: p  0.35, t  0.93
10: p  0.002, t  3.41
30: p  0.0001, t  6.15
KO (compared to saline):
5: p  0.81, t  0.24
10: p  0.36, t  1.28
30: p  0.003, t  3.45
Multiple comparison, Genotype, df  87:
Saline: p  0.45, t  0.76
5: p  0.34, t  1.32
10: p  0.03, t  2.59
30: p  0.02, t  2.97
1B–D
Cocaine administration in open
field after a 120-min
habituation (PICK1 KO and
WT mice); drug comparison of
60 min before and after
administration
Normal distribution Three-way ANOVA of injection (last 60
min of habituation vs first 60 min of
drug primed), genotype (WT vs KO),
and
treatment (0- vs 10- vs 30-mg/kg
cocaine)










Injection: p  0.0001, F  131.69, df  1
Genotype: p  0.048, F  4.16, df  1
Treatment: p  0.0001, F  14.24, df  2
Genotypetreatment: p  0.21, F  1.62, df  2
t test:
Genotype effect after drug administration:
Saline: p  0.732, t  -0.355, df  8
10: p  0.01, t  2.87, df  17
30: p  0.44, t  0.821, df  16
2A
Sensitization overview
NA NA NA NA
2B
Cocaine sensitization of WT mice






Sensitization (day 1 vs 6)
Day: p  0.04, F  4.61, df 1
Daygenotype: p  0.72, F  0.13, df  1
Daytreatment: p  0.0001, F  28.73, df  1
Daygenotypetreatment: p  0.79, F  0.07, df  1
Maintenance of sensitization (day 6 vs 12 vs 20)
Day: p  0.01, F  5.13, df  2
Daygenotype: p  0.46, F  5.13, df  2
Daytreatment: p  0.01, F  5.32, df  2
Daygenotypetreatment: p  0.71, F  0.35, df  2
2C
Self-administration with cocaine





p  0.61, F(4,70)  0.68
Cocaine doses:
p  0.0009, F(4,70)  5.28
Genotype:









p  0.87, F(4,85)  0.30
Food concentration:
p  0.0001, F(4,85)  18.82
Genotype:
p  0.43, F(1,85)  0.63
3A–C
SKF administration in open field
after a 120-min habituation
(PICK1 KO and WT mice);
drug comparison of 60 min
before and after administration
Normal distribution Three-way ANOVA of injection (last 60
min of habituation vs first 60 min of
drug primed), genotype (WT vs KO),
and
treatment (0- vs 0.1- vs 1-mg/kg
cocaine)










Injection: p  0.0001, F  341.98, df  1
Genotype: p  0.22, F  1.58, df  1
Treatment: p  0.0001, F  21.15, df  2
Genotypetreatment: p  0.75, F  0.29, df  2
3D–F
Quinpirole administration in open
field after a 120-min
habituation (PICK1 KO and
WT mice); drug comparison of
60 min before and after
administration
Normal distribution Three-way ANOVA of injection (last 60
min of habituation vs first 60 min of
drug primed), genotype (WT vs KO),
and
treatment (0- vs 0.1- vs 10- mg/kg
cocaine)









Injection: p  0.0001, F  170.29, df  1
Genotype: p  0.81, F  0.06, df  1
Treatment: p  0.44, F  0.83, df  2
Genotypetreatment: p  0.45, F  0.83, df  2
(Continued)
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test Sample size Statistical data
3G
Surface levels of D1R




p  0.13 (two tailed), t  1.91, df  4
3H
Striatal CREB protein levels




p  0.61 (two tailed), t  0.53, df  7
3I
Striatal p-CREB protein levels




p  0.98 (two tailed), t  0.03, df  3
4A
Vmax of synaptosomal DA uptake
in WT vs PICK1 KO mice
Assuming
normality




Vmax: p  0.025 (two tailed), t  3.48, df  4
Km: p  0.23 (two tailed), t  1.43, df  4
4B
Saturation curve of synaptosomal
DA uptake in WT vs PICK1
KO mice
NA NA NA NA
4C
Surface levels of DAT
Assuming
normality




p  0.39 (two tailed), t  1.01, df  3
4D








p  0.36 (two tailed), t  1.18, df  2
4E
Vmax of synaptosomal DA uptake
in WT vs DAT  Ala mice
Assuming
normality




Vmax: p  0.03 (two tailed), t  2.74, df  6
Km: p  0.04 (two tailed), t  2.67, df  6
4F
Saturation curve of synaptosomal
DA uptake in WT vs DAT 
Ala mice
NA NA NA NA
4G
Cocaine administration in activity
boxes with no habituation
(DAT  Ala and WT mice)













p  0.48, F(3,74)  0.84
Treatment:
p  0.0001, F(3,74)  20.31
Genotype:
p  0.99, F(1,74)  4.810e-005
Multiple comparison, Treatment, df  74:
WT (compared to saline):
5: p  0.12, t  1.56
10: p  0.003, t  3.25
30: p  0.0001, t  5.97
KO (compared to saline):
5: p  0.03, t  2.5
10: p  0.03, t  2.41
30: p  0.0001, t  4.91
Multiple comparison, Genotype, df  74:
Saline: p  0.76, t  0.44
5: p  0.76, t  1.04
10: p  0.76, t  0.67
30: p  0.76, t  0.89
5A
Striatal DA levels measured by
HPLC analysis




p  0.01, t  3.02, df  12
5B
Peak amplitude of KCl-evoked
DA release




p  0.04, t  2.35, df  10
5C
Trace of peak amplitude of KCl-
evoked DA release
NA NA NA NA
5D
Striatal VMAT2 protein levels




p  0.54, t  0.66, df  5
(Continued)
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30-mg/kg cocaine intraperitoneal by increased locomotor
activity, while KO mice showed a significantly attenuated
locomotor response with treatment effect only at the high-
est dose of cocaine (F(3,87)  17.5, p  0.0001, wild type:
5 mg/kg; t(87)  0.93, p  0.35, 10 mg/kg; t(87)  3.41,
p  0.002, 30 mg/kg; t(87)  6.15, p  0.0001, KO: 5
mg/kg; t(87)  0.24, p  0.81, 10 mg/kg; t(87)  1.28, p 
0.36, 30 mg/kg; t(87)  3.45, p  0.003; Fig. 1A).
We then used an open field test to investigate cocaine-
induced hyperactivity following a 120-min habituation pe-
riod (Fig. 1B–D). Three-way ANOVA comparing injection
(activity 60 min before vs after drug injection), genotype
(wild type vs KO) and treatment (0- vs 10- vs 30-mg/kg
cocaine), revealed significant effects of genotype, treat-
ment and injection (pre vs post; FGENOTYPE  4.16, df  1,
p  0.048, FTREATMENT  14.24, p  0.0001, df  2,
FINJECTION 131.69, p 0.0001, df 1, FGENOTYPETREATMENT
 1.62, p  0.21, df  2; Fig. 1B) with post hoc analysis
revealing a significant difference at 10-mg/kg cocaine
(saline; t(8)  0.36, p  0.73, 10 mg/kg; t(17)  2.87, p 
0.01, 30 mg/kg; t(16)  0.82, p  0.44; Fig. 1C) supporting
the observation that the attenuated cocaine-induced lo-
comotor response in PICK1 KO mice is present both with






test Sample size Statistical data
5E
Striatal TH protein levels




p  0.008, t  3.38, df  9
5F
Striatal pTH protein levels
Assuming
normality




p  0.38, t  1.12, df  2
5G
Midbrain TH protein levels




p  0.92, t  0.1, df  7
5H
Midbrain pTH protein levels
Assuming
normality




p  0.46, t  0.90, df  2
5I
Midbrain TH mRNA levels
Assuming
normality




p  0.89, t  0.16, df  2
6A

















and PICK1 in striatum and
midbrain




Staining of GFP  TH  PICK1












TH levels following PICK1 KD in
rat dopaminergic neurons








p  0.009, t  2.68, df  78
6F
PICK1 levels following PICK1 KD
in rat dopaminergic neurons
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Figure 1. Impaired locomotor response to cocaine in PICK1 KO mice. A, Mice were injected with the indicated doses of cocaine and
locomotor activity (beam breaks) was recorded for 1 h. Two-way ANOVA followed by Holm–Sidak post hoc analysis revealed an
overall significant difference between the genotypes (FGENOTYPE(1,87)  14.91, p  0.0002, FTREATMENT(3,87)  17.5, p  0.0001,
FINTERACTION(3,87)  1.88, p  0.32) with multiple comparison revealing genotype differences in the behavioral response to both 10-
and 30-mg/kg cocaine (saline; t(87)  0.76, p  0.45, 5 mg/kg; t(87)  1.32, p  0.342, 10 mg/kg; t(87)  2.59, p  0.033, 30 mg/kg;
t(87)  2.97, p  0.015). B–D, Mice were placed in open field boxes and left to habituate for 120 min before being injected with the
indicated doses of cocaine. Locomotor activity (distance moved in meters) was recorded for 2 h after cocaine injection. Analysis of
the 60 min before and after drug injection reveals a significantly impaired cocaine response in the PICK1 KO mice (FGENOTYPE  4.16,
df  1, p  0.048, FTREATMENT  14.24, p  0.0001, df  2, FINJECTION  131.69, p  0.0001, df  1, FGENOTYPETREATMENT  1.62, p 
0.21, df 2). C, Locomotor activity of the last 60 min before drug injection. D, Locomotor activity of the first 60 min after drug injection
with post hoc analysis revealing a significant difference at 10-mg/kg cocaine (saline; t(8)  0.36, p  0.73, 10 mg/kg; t(17)  2.87, p
 0.01, 30 mg/kg; t(16)  0.82, p  0.44). WT, wild type;  indicates versus own saline, # indicates genotype comparisons. All data
expressed as mean  SEM.
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Decreased number of self-administered cocaine
reinforcements in PICK1 KO mice
We next assessed whether the lack of PICK1 affected
long-term behavioral effects of cocaine by testing PICK1
KO mice in a sensitization paradigm (Fig. 2). Mice were
given daily injections of 10-mg/kg cocaine for 6 d followed
by cocaine challenges on day 12 and day 20 (Fig. 2A).
Control groups were given saline on the six induction days
and cocaine on challenge days. Cocaine instigated in-
creased cocaine-induced locomotor activity with progres-
sively increasing response to cocaine in both wild-type
and PICK1 KO mice with significant sensitization and no
genotype difference (FDAY1versus6 4.61, p 0.04, df 1,
FDAYGENOTYPE 0.13, p 0.72, df 1, FDAYTREATMENT
28.73, p  0.0001, df  1, FDAYGENOTYPETREATMENT 
0.07, p  0.79, df  1; Fig. 2B). In addition, there was no
genotype difference in the maintenance of sensitization
(FDAY6versus12vs20  5.13, p  0.01, df  2, FDAYGENOTYPE 
B
A



































































Figure 2. Maintained cocaine sensitization but fewer cocaine reinforcements in PICK1 KO mice. A, Overview of the cocaine
sensitization paradigm. B, Cocaine sensitization of wild-type and PICK1 KO mice given daily doses of 0- or 10-mg/kg cocaine for 6
d followed by two challenges were all mice were given 10-mg/kg cocaine. Cocaine induced increased locomotion with no overall
genotype difference (FDAY1versus6  4.61, p  0.04, df  1, FDAYGENOTYPE  0.13, p  0.72, df  1, FDAYTREATMENT  28.73, p 
0.0001, df  1, FDAYGENOTYPETREATMENT  0.07, p  0.79, df  1) and no difference in sensitization maintenance (FDAY6versus12vs20 
5.13, p  0.01, df  2, FDAYGENOTYPE  5.13, p  0.46, df  2, FDAYTREATMENT  5.32, p  0.01, df  2, FDAYGENOTYPETREATMENT 
0.35, p  0.71, df  2). C, Operant responding for cocaine in PICK1 KO and wild-type mice. PICK1 KO mice obtained significantly
fewer cocaine reinforcements compared to wild-type mice in cocaine-maintained responding under a FR1 schedule of cocaine
self-administration (FINTERACTION(4,70)  0.68, p  0.61, FCOCAINEDOSE(4,70)  5.28, p  0.0009, FGENOTYPE(1,70)  4.46, p  0.04). D,
Operant responding for liquid food in PICK1 KO and wild-type mice. Food-maintained operant behavior under the FR 1 schedule of
reinforcement did not differ between PICK1 KO and wild-type mice (FINTERACTION(4,85)  0.30, p  0.87, FFOODDOSE(4,85)  18.82,
p  0.0001, FGENOTYPE(1,85)  0.63, p  0.43). All data expressed as mean  SEM.
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5.13, p  0.46, df  2, FDAYTREATMENT  5.32, p  0.01,
df 2, FDAYGENOTYPETREATMENT 0.35, p 0.71, df 2;
Fig. 2B).
We further explored whether lack of PICK1 affected
cocaine’s reinforcing properties by testing PICK1 KO
mice in an intravenous cocaine self-administration para-
digm. PICK1 KO mice learned to self-administer cocaine
as fast as their wild-type counterparts (Table 2), i.e., both
genotypes acquired the task with similar number of rein-
forcers earned as well as days spent to reach criteria for
baseline, extinction, and re-baseline (Table 2). However,
when subsequently examining the dose-effect relation-
ship (saline, 0.03, 0.1, 0.3, 1.0 mg/kg per infusion of
cocaine), KO mice obtained significantly fewer cocaine
reinforcements (FINTERACTION(4,70)  0.68, p  0.61, FCO-
CAINE DOSE(4,70)  5.28, p  0.0009, FGENOTYPE(1,70)  4.46,
p  0.04; Fig. 2C) indicating an effect of lacking PICK1 on
long-term effects of cocaine. A group of naïve mice was
used for the control experiment with liquid food self-
administration. While PICK1 KO mice were slightly slower
to learn this task and earned fewer reinforcements during
this phase of training, no differences were seen between
genotypes during extinction and re-baseline criteria
(Table 2), or during assessment of the dose-effect relation-
ship (FINTERACTION(4,85)  0.30, p  0.87, FFOOD DOSE(4,85) 
18.82, p  0.0001, FGENOTYPE(1,85)  0.63, p  0.43; Fig.
2D), which indicates that the deficit in the self-
administration paradigm primarily is related to cocaine.
We should note, however, that mice were food restricted
during the liquid food self-administration experiments,
which, according to previous investigations, might affect
DA dynamics (Roseberry, 2015; Jones et al., 2017).
Preserved DA receptor activation and signal
transduction in PICK1 KO mice
To investigate whether the attenuated locomotor re-
sponse to cocaine might result from aberrant postsynap-
tic D1R signaling in PICK1 KO mice, we challenged mice
with the selective D1R agonist SKF82958 in the open
field paradigm (Fig. 3A–C). Stimulation of DA D1R by
SKF82958 has previously been shown to promote hyper-
locomotor activity in mice and activation of downstream
effectors similar to the effects of cocaine (Jeon et al.,
2010; Beaulieu and Gainetdinov, 2011). DA D1R agonist
stimulation induced significantly increased locomotor ac-
tivity without genotype difference (FGENOTYPE  1.58, df 
1, p  0.22, FTREATMENT  21.15, p  0.0001, df  2,
FGENOTYPETREATMENT 0.29, p 0.75, df 2; Fig. 3A–C).
We also tested a D2-receptor agonist quinpirole in a sim-
ilar paradigm. Mice of both genotypes were allowed to
habituate for 120 min followed by administration of quin-
pirole and assessment of locomotor activity. The treatment
produced no significant difference between genotypes
(FINJECTION  170, df 1, p 0.001, FGENOTYPE 0.06, df
1, p  0.81, FTREATMENT  0.83, p  0.44, df  2, FGENOTYPE-
TREATMENT  0.83, p  0.45, df  2; Fig. 3D–F).
To investigate potential postsynaptic biochemical alter-
ations in these mice, we probed the level of surface-
expressed D1R using surface biotinylation in striatal slices
(Fig. 3G). D1R surface expression was unaltered in PICK1
KO mice compared to wild-type mice (t(4)  1.91, p 
0.13; Fig. 3G). Furthermore, we prepared striatal lysates
from wild-type and PICK1 KO mice and investigated ex-
pression and phosphorylation levels of cAMP response
element binding (CREB) (Fig. 3H,I), a downstream effector
of dopaminergic signaling (Beaulieu and Gainetdinov,
2011). Immunoblotting of striatal lysates showed that
CREB levels in PICK1 KO mice (t(7)  0.53, p  0.61; Fig.
3H) as well as levels of CREB pSer133 (t(3)  0.03, p 
0.98; Fig. 3I) were unaltered. Together, these data sug-
gest that reduced behavioral responses of PICK1 KO
mice to cocaine are unlikely due to compromised post-
synaptic dopaminergic neurotransmission.
PICK1 KO mice display reduced DA re-uptake
despite preserved DAT surface expression
We have previously reported that the expression and
distribution of DAT in striatum of PICK1 KO mice are
unaffected compared to wild-type mice (Rickhag et al.,
2013). Here, we investigated whether the attenuated be-
havioral effects of cocaine (Figs. 1, 2) could be related to
compromised presynaptic DAT function. We therefore
assessed functional levels of DAT in striatum by evaluat-
ing [3H]-DA uptake in synaptosomal preparations. Inter-
estingly, we found significantly reduced DA uptake
capacity in PICK1 KO mice compared to wild-type con-
trols (Vmax 72.7  24% of wild type; t  3.48, p  0.03,
df 4; Fig. 4A) without a change in DA affinity (Km for wild
type: 84  23 nM; Km for KO: 50  5 nM, t  1.43, p 
0.23, df  4). Levels of surface expressed DAT, however,
was not significantly reduced as determined by surface
biotinylation experiments on striatal slices (t(3) 1.01, p
0.39; Fig. 4C). We were also unable to detect any change
in microdomain compartmentalization of DAT in the
Table 2. Mean number of days/reinforcers to reach criteria
Days RNF
WT KO WT KO
Cocaine FR1 baseline 4.1  0.6 3.9  0.6 31.4 4.1 25.6  1.8
Cocaine FR1 extinction 2.6  0.4 2.1  0.2 12.1 1.7 12.3  1.8
Cocaine FR1 re-baseline 2.3  0.6 2.4  0.5 34.7 4.3 42.2  9.0
Liquid food FR1 baseline 2.9  0.3 5.0  0.7 118.1 5.8 92.1  9.0
Liquid food FR1 extinction 1.6  0.2 1.3  0.2 49.6 5.9 42.6  5.8
Liquid food FR1 re-baseline 2.9  1.1 1.5  0.3 156.321.3 118.8  8.6
Mice were trained with either cocaine or liquid food under FR1 schedule of reinforcement. PICK1 KO mice showed significantly lower liquid food reinforce-
ments at FR1 acquisition criteria which was also reached slower than wild-type mice; unpaired t test; data are group mean  SEM. Cocaine: nWT  8 and
nKO  8; liquid food: nWT  9 and nKO  10.
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Figure 3. Preserved postsynaptic DA D1R signaling in PICK1 KO mice. A–C, Mice were placed in open field boxes and left to habituate
for 120 min before being injected with the indicated doses of SKF82958. Locomotor activity (distance moved in m) was recorded for
2 h after drug injection. Analysis of the 60 min before and after drug injection reveals a treatment effect, with no genotype difference
on genotype response (FGENOTYPE  1.58, df  1, p  0.22, FTREATMENT  21.15, p  0.0001, df  2, FGENOTYPETREATMENT  0.29,
p  0.75, df  2). B, Locomotor activity of the last 60 min before drug injection. C, Locomotor activity of the first 60 min after drug
injection. D–F, Mice were placed in open field boxes and left to habituate for 120 min before being injected with the indicated doses
of quinpirole. Locomotor activity (distance moved in m) was recorded for 2 h after drug injection. Analysis of the 60 min before and
after drug injection reveals no genotype difference on the behavioral effects of quinpirole (FGENOTYPE  0.06, df  1, p  0.81,
FTREATMENT  0.83, p  0.44, df  2, FGENOTYPETREATMENT  0.83, p  0.45, df  2). E, Locomotor activity of the last 60 min before
drug injection. F, Locomotor activity of the first 60 min after drug injection. G, Immunoblotting of striatal lysates demonstrates that
surface levels of D1R is unchanged in PICK1 KO mice (t(4)  1.91, p  0.13). Left panel, Densitometric analysis of immunoblot for
wild-type and PICK1 KO mice. Right panel, Representative immunoblot for D1R and Na-K-ATPase in wild-type and PICK1 KO mice.
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plasma membrane of striatal slices (Fig. 4D). Indeed,
previous data have supported that DAT is sequestered
into cholesterol-enriched microdomains or membrane
rafts in the plasma membrane (Adkins et al., 2007;
Cremona et al., 2011). According to sucrose gradient
fractionation experiments, DAT was to a similar degree
segregated into the detergent-resistant (membrane raft)
fractions, together with the membrane raft marker flo-
tilin 1 (Flot1), in lysates from PICK1 KO mice compared
to wild-type lysates (t(2)  1.18, p  0.36; Fig. 4D).
Together, the data demonstrate that decreased DA
uptake in PICK1 KO mice cannot be explained by de-
creased DAT expression and membrane distribution in
striatum.
Compromised DA re-uptake but preserved
locomotor response to cocaine in DAT knock-in
mice with disrupted PDZ-binding motif
We have previously generated knock-in mice express-
ing DAT mutants incapable of binding PDZ-domain pro-
teins such as PICK1 (Rickhag et al., 2013). These mice
show reduced striatal DAT expression, but given the un-
changed expression and distribution of DAT in PICK1 KO
mice, the reduced striatal DAT expression in these mice
was unlikely the result of disrupted PICK1 binding (Fig.
4A–C; Rickhag et al., 2013). Interestingly, however, in DAT
 Ala mice, we found that the [3H]-DA uptake capacity
was significantly reduced as seen in PICK1 KO mice. The
measured DA uptake in synaptosomes from DAT  Ala
mice was 63% of wild-type (DAT  Ala: Vmax 63  6%
of wild type, t  2.74, p  0.03; Fig. 4E,F) compared to
73% for PICK1 KO mice (Fig. 4A,B). Nonetheless, the
DAT  Ala mice displayed unchanged cocaine-induced
hyperactivity compared to wild-type littermates at all of
the tested cocaine doses (5, 10, and 30 mg/kg, i.p.;
FINTERACTION(3,74)  0.84, p  0.48, FTREATMENT(3,74) 
20.31, p  0.0001, FGENOTYPE(1,74)  4.810e-005, p 
0.99; Fig. 4G). These data suggest that the attenuated
behavioral response to cocaine in PICK1 KO mice is
unrelated to PICK1-DAT interactions, or to the 20–30%
reduction in DAT reuptake capacity in PICK1 KO mice.
Evidence for altered DA homeostasis in PICK1 KO
mice
To correlate putative dysregulation of DA homeostasis
with altered behavioral responses in PICK1 KO mice, we
tested markers for DA synthesis, DA reuptake and vesic-
ular storage together with DA release kinetics from intact
striatal terminals. Strikingly, striatal DA content was sig-
nificantly elevated in PICK1 KO mice as measured by
high-performance liquid chromatography analysis of stri-
atal lysates (t(12)  3.02, p  0.01; Fig. 5A). To investigate
if increased striatal pools of DA were associated with
functional consequences in vivo, we used high-speed
chronoamperometric recordings in striatum to measure
DA release in PICK1 KO and littermate wild-type mice.
KCl was pressure-ejected into striatum of anaesthetized
mice to evoke DA release. In agreement with increased
striatal DA content, KCl pressure-ejection locally into
striatum elicited two-fold greater DA release in PICK1 KO
mice relative to wild-type mice (t(10)  2.35, p  0.04;
peak amplitude for wild type: 0.61 M; KO: 1.24 M; Fig.
5B). Representative traces of DA release in mouse stria-
tum on KCl stimulation are shown in Figure 5C. Clearance
rate (wild type: 46  11 nM/s; KO: 72  26 nM/s) was not
significantly different between genotypes; however, we
should note that it is difficult to interpret precisely these
rates given that KCl-induced DA release likely continues
simultaneously with clearance, especially during the
initial phase of the descending limb of the signal. None-
theless, in sum, elevated evoked DA release in PICK1
KO mice supports our finding of increased DA content
in striatum.
Vesicular monoamine transporter 2(VMAT2) plays an
essential role in DA homeostasis by sequestering DA into
synaptic vesicles. However, VMAT2 expression in striatal
preparations was not significantly different between ge-
notypes (t(5)  0.66, p  0.54; Fig. 5D), implying that
elevated DA in striatum is not associated with increased
VMAT2 expression.
Immunoblotting showed that levels of the rate-limiting
enzyme of DA synthesis, TH, were significantly increased
in striatal terminals from PICK1 KO mice (t(9)  3.38, p 
0.008; Fig. 5E). Since TH phosphorylation at Ser40 by
protein kinase A positively regulates catalytic activity of
TH (Lindgren et al., 2000), we determined TH phosphor-
ylation at Ser40. The relative phosphorylation of this site,
however, was not different between genotypes (t(2) 
1.12, p  0.38; Fig. 5F). We also determined TH levels in
the ventral midbrain from where the mesostriatal DA pro-
jections originate, and thus, in the somatodendritic com-
partment of dopaminergic neurons (Björklund and
Dunnett, 2007). In ventral midbrain lysates, levels of TH
were not different between the genotypes (t(7)  0.1, p 
0.92; Fig. 5G) suggesting differential regulation of TH in
neuronal perikarya compared to axonal terminals in stria-
tum. In addition, we observed no difference in the relative
phosphorylation of Ser40 in TH (t(2)  0.90, p  0.46; Fig.
5H). Importantly, quantitative PCR analysis from midbrain
preparations revealed no alterations in TH mRNA levels in
the absence of PICK1, which eliminate the possibility that
transcriptional changes can account for the phenotype
(t(2)  0.16, p  0.89; Fig. 5I).
PICK1 is localized to TH-expressing neurons in
ventral midbrain
To further explore whether PICK1 indirectly or directly,
acts as a negative regulator of striatal TH levels without
continued
H, I, Immunoblotting of striatal lysates show unaltered expression levels of CREB and pCREB in PICK1 KO mice compared to
wild-type controls (CREB: t(7)  0.53, p  0.61, pCREB: t(3)  0.03, p  0.98). Upper panels, Densitometric analysis of immunoblots
for CREB and pCREB in wild-type and PICK1 KO mice. Lower panels, Representative immunoblots for pCREB and -actin in
wild-type and PICK1 KO mice. All data expressed as mean  SEM.
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Figure 4. PICK1 KO mice show unaltered cellular distribution of DAT but reduced striatal DA uptake. DAT  Ala knock-in mice with
a disrupted PDZ-binding motif demonstrate similar loss of DA uptake, albeit preserved locomotor response to cocaine. A, B, DA
uptake in striatal synaptosomes from PICK1 KO mice and wild-type controls. Reduced DA uptake in striatal preparations from
PICK1 KO mice (Vmax 72.7  24% of wild type; t  3.48, p  0.03, df  4; A). B, Normalized saturation curve for DA uptake
in striatal synaptosomes from PICK KO mice and wild-type littermate controls (maximal uptake capacity Vmax: wild type  57.6
 4.3 fmol/min/g; KO  41.9  1.4 fmol/min/g, mean  SEM). C, Surface biotinylation of striatal slices demonstrate that
PICK1 KO mice have preserved surface-expressed DAT compared to wild-type (t(3)  1.01, p  0.39). Left panel, Densitometric
analysis of immunoblots from wild-type and PICK1 KO mice. Right panel, Representative immunoblots for DAT and Na-K-
ATPase. D, Sucrose gradient centrifugation using striatal preparations show unaltered membrane distribution between the
fractions with high and low buoyancy in PICK1 KO mice when compared to wild type. Left panel, Western blotting of a
representative sucrose gradient fractionation from striatal lysates in a gradient from 15% to 40% and immunoblots for DAT,
flottilin-1 (a marker of membrane rafts), and Na-K-ATPase. Right panel, Densitometric analysis showing the fraction of DAT
distribution to nonsoluble (high buoyancy) fractions compared to wild-type controls (t(2)  1.18, p  0.36). E, DA uptake in
striatal synaptosomes from DAT  Ala mice and wild-type controls. Reduced DA uptake in striatal preparations from DAT  Ala
(Vmax 63  6% of wild type, t  2.74, p  0.03). F, Normalized saturation curve for DA uptake in striatal synaptosomes from
DAT  Ala mice and wild-type littermate controls (maximal uptake capacity Vmax: wild type  49.87  6.0 fmol/min/g; KO 
31.36  3.1 fmol/min/g, mean  SEM). G, Assessment of cocaine-induced locomotor hyperactivity shows no genotype
difference (FINTERACTION(3,74)  0.84, p  0.48, FTREATMENT(3,74)  20.31, p  0.0001, FGENOTYPE(1,74)  4.810e-005, p  0.99).
Black and green bars represent wild-type and corresponding DAT  Ala mice. There was no treatment difference between
treatment groups. All data expressed as mean  SEM.
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Figure 5. Increased TH protein levels and DA content in striatum, correlates with enhanced DA release in PICK1 KO mice. A,
Total DA content in striatal homogenates from PICK1 KO mice and wild-type controls as measured by HPLC. PICK1 KO mice
show significantly elevated DA content in striatum (128% of wild type, t(12)  3.02, p  0.01). B, C, Enhanced vesicular DA
release in striatum of PICK1 KO mice as measured by high-speed in vivo chronoamperometry. Data show peak amplitude on
KCl-evoked DA release in striatum (t(10)  2.35, p  0.04). The same amount of KCl pressure-ejected locally into striatum elicited
2-fold greater DA release in PICK1 KO mice relative to wild-type mice. Shown are representative oxidation currents, converted
to a micromolar concentration using a calibration factor determined for each electrode in vitro. D, Immunoblotting from striatal
lysates shows unchanged VMAT2 expression in PICK1 KO mice (t(5)  0.66, p  0.54). E, Immunoblotting revealed elevated TH
protein expression in striatal lysates from PICK1 KO mice (t(9)  3.38, p  0.008). Upper panels, Densitometric analysis of
immunoblots for wild-type and PICK1 KO mice. Lower panels, Representative immunoblots for TH and -actin in wild-type and
PICK1 KO mice. F, Phosphorylation of TH at serine-40 is unaltered in striatum of PICK1 KO mice (t(2)  1.12, p  0.38). Upper
panels, Densitometric analysis of immunoblots for wild-type and PICK1 KO mice. Lower panels, Representative immunoblots for
pTH and -actin in wild-type and PICK1 KO mice. G, Immunoblotting from ventral midbrain lysates show unchanged TH
expression in PICK1 KO mice (t(7)  0.1, p  0.92). H, Immunoblotting from ventral midbrain lysates show unchanged pTH
expression in PICK1 KO mice (t(2)  0.90, p  0.46). I, Quantitative PCR analysis show unaltered TH mRNA levels in midbrain
of PICK1 KO mice compared to wild-type control (t(2)  0.16, p  0.89). All data expressed as mean  SEM.
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changing the balance between TH and phosphorylated
TH, we performed immunofluorescence for PICK1 and TH
in midbrain slices. Previous reports demonstrate immu-
nolabeling of PICK1 both at pre- and postsynaptic sites in
cortex, hippocampus, cerebellum and striatum (Haglerød
et al., 2009, 2017). Here, we report using an optimized
immunohistochemistry protocol with tyramide signal am-
plification, immunofluorescence of PICK1 in midbrain do-
paminergic neurons as evidenced by colabeling with TH
(Fig. 6A) supporting a previous study validating PICK1
expression in dopaminergic neurons (Torres et al., 2001).
PICK1 expression was localized predominantly in the cy-
tosolic compartment of TH-expressing neurons in a po-
larized fashion with a punctate pattern. The immunosignal
of PICK1 showed clear overlap with the TH signal, which
as expected (Apuschkin et al., 2015) was localized to the
cytosol, although more diffuse in its distribution as com-
pared to that of PICK1 (Fig. 6A). Importantly, no PICK1
signal was seen in slices from PICK1 KO mice.
With the binding promiscuity of the PICK1 PDZ-domain
in mind (Erlendsson et al., 2014), we assessed whether TH
could be a PICK1 PDZ-domain binding partner. We used
a fluorescence polarization assay and measured the abil-
ity of a peptide corresponding to the 11 most C-terminal
residues of mouse TH (mTH C11) to inhibit binding of
purified PICK1 to a fluorescently tagged peptide corre-
sponding to the most 13 C-terminal residues of the known
PICK1 interaction partner DAT (OrgDATC13). Whereas the
unlabeled DAT peptide (mDATC13) potently inhibited
binding of OrgDATC13, the potency of mTHC11 was
several orders of magnitude weaker (Fig. 6B). This ex-
cludes canonical high-affinity binding of TH to the PICK1
PDZ-domain but does not exclude a noncanonical bind-
ing mode between the two proteins as, for example, seen
for the PICK1:Arf1 interaction (Takeya et al., 2000; Rocca
et al., 2013; Erlendsson et al., 2014). We therefore also
performed coimmunoprecipitation experiments on both
midbrain and striatal lysates. However, in both lysates
neither immunoprecipitation of PICK1 nor TH led to co-
precipitation of TH or PICK1, respectively (Fig. 6C), further
arguing against direct interaction between the two pro-
teins.
KD of PICK1 in midbrain dopaminergic neurons
enhances TH expression
We hypothesized that KD of PICK1 specifically in DA
neurons would result in elevated TH expression as ob-
served in striatal lysates from PICK1 KO mice. Despite the
lack of a direct PDZ-domain-mediated protein-protein in-
teraction between TH and PICK1 (Fig. 6B), elevated TH
and DA levels in PICK1 KO mice could indicate an indirect
role for PICK1 in the regulation of TH expression and
thereby DA synthesis. We used a dual promoter lentiviral
vector to simultaneously KD PICK1 with shRNA under
control of the human H1 promoter and eGFP under con-
trol of the ubiquitin promoter for identification of trans-
duced neurons. Cells that were double positive for GFP
and TH staining were imaged and identified as neurons of
interest. Immunostaining showed widespread, diffuse
eGFP distribution in transduced neurons (Fig. 6D, top
panel), TH staining showed cytosolic localization (Fig. 6D,
middle panel), while PICK1 expression was particularly
punctate (Fig. 6D, lower panel) consistent with the brain
slice imaging (Fig. 6A). Transduction with PICK1 shRNA
resulted in an efficient PICK1 KD (Fig. 6D, lower right
panel, F). Remarkably, the KD of PICK1 in dopaminergic
neurons caused a significant increase in TH levels (t(78) 
2.68, p  0.009 (127% compared to wild type, control
GFP vs ShPICK1 GFP; Fig. 6D, middle panel, E), which is
in accordance with the increased TH found in the PICK1
KO mice.
Discussion
PICK1 is known to interact via its PDZ-domain with a
range of different membrane proteins and kinases (Xu and
Xia, 2006; Li et al., 2016) including DAT, which is the main
target for the stimulatory actions of cocaine (Giros et al.,
1996). The significance of PICK1 for the actions of co-
caine has nonetheless remained elusive. Our study dem-
onstrates that PICK1 is critical for both acute and chronic
behavioral actions of cocaine. In addition, our data reveal
a striking role of PICK1 in regulating DA homeostasis. This
regulation appears to be unrelated to PICK1’s interaction
with DAT, but likely involves negative regulation of striatal
TH expression, as reflected by increased levels of TH and
DA in striatum, as well as enhanced DA release in PICK1
KO mice.
The widely abused psychostimulant cocaine inhibits
DAT leading to a rise in extracellular DA, stimulation of DA
receptors, and a dose-dependent hyperlocomotion (Giros
and Caron, 1993; Giros et al., 1996). This increase in
locomotor activity in response to cocaine was markedly
attenuated in PICK1 KO mice (Fig. 1). In addition, PICK1
KO mice obtained significantly fewer cocaine reinforce-
ments in an intravenous self-administration paradigm of
cocaine (Fig. 2C). Importantly, cocaine self-administration
(Kmiotek et al., 2012) assesses motivational aspects of
cocaine seeking in contrast to sensitization (Post and
Rose, 1976; Steketee and Kalivas 2011), which involves
passive cocaine administration and only assesses loco-
motion. Overall, these data support critical involvement of
PICK1 in both acute effects of and chronic, neuroadaptive
behavioral changes induced by cocaine. A role of PICK1
in changes induced by cocaine has been indicated previ-
ously in studies showing that disruption of PICK1-GluA2
interactions abolish cocaine-induced synaptic plasticity in
striatum and VTA (Bellone and Lüscher, 2006; Famous
et al., 2008). Furthermore, inhibition of PICK1 in nucleus
accumbens attenuates reinstatement of cocaine seeking
(Famous et al., 2008; Schmidt et al., 2011).
Our data suggest that postsynaptic DA signaling is not
important for the diminished behavioral effects of cocaine
in PICK1 KO mice. When PICK1 KO mice were challenged
with a D1R agonist, we observed dose-dependent in-
creases in locomotor activity that did not differ from wild-
type littermates (Fig. 3A–C). Additionally, we observed no
behavioral difference between genotypes when challeng-
ing the mice with a D2R agonist (Fig. 3D–F), and striatal
levels of CREB/pCREB were not different between geno-
types (Fig. 3H,I). Our results also suggest that the atten-
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Figure 6. PICK1 is expressed in TH-positive midbrain neurons and lentiviral KD in midbrain dopaminergic cell cultures causes
elevated TH expression. A, Immunohistochemical analysis demonstrates PICK1 immunofluorescence in TH-expressing neurons in
ventral midbrain. Neuronal cell bodies in ventral midbrain show diffuse TH distribution in the entire cytosol while PICK1 immunoflu-
orescence is clustered and polarized in the neuronal cell bodies. Scale bar: 10 m. B, Competition fluorescence polarization indicates
a non-PDZ-mediated interaction between TH and PICK1. Graph displays the competition of the OrgDAT with unlabelled TH-C11,
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uated behavioral effects of cocaine in PICK1 KO mice are
unrelated to the interaction between PICK1 and DAT (Fig.
4A–D). Previous investigations based on a yeast two-
hybrid screen and coimmunoprecipitation experiments
suggested a direct interaction between DAT and PICK1
(Torres et al., 2001). Nonetheless, conflicting data exist
regarding the influence of PICK1 on DAT function. Over-
expression of PICK1 was found to enhance DAT surface
expression and DA uptake in heterologous cell lines and
immortalized dopaminergic neurons (Torres et al., 2001).
However, later studies reported that PICK1 lacks influ-
ence on both DAT surface levels and DA uptake (Bjerg-
gaard et al., 2004; Madsen et al., 2012) and we previously
showed that total DAT protein expression is unchanged in
PICK1 KO mice (Rickhag et al., 2013). Here, we find
unaltered DAT surface expression in the PICK1 KO mice
(Fig. 4C) concomitant with preserved microdomain distri-
bution in striatum (Fig. 4D). In sum, these data suggest
that PICK1 is not critical for overall DAT surface distribu-
tion in striatal terminals. Despite preserved DAT distribu-
tion, however, we observed a decrease in synaptosomal
DA uptake in PICK1 KO mice (Fig. 4A,B).
We recently described DAT knock-in mice that express
mutations hindering the interaction between the DAT
C-terminus and PDZ-domain scaffold proteins. For the
DAT  Ala mice, expressing a mutation with an extra
alanine added to the C-terminus, we reported a marked
reduction in striatal DAT protein expression (Rickhag
et al., 2013). Here, we show that the reduction in protein
expression is paralleled by a reduction in DA uptake (Fig.
4E,F). These observations contrast the PICK1 KO mice in
which DAT expression and distribution are unchanged
compared to wild-type mice despite similar reduction of
DA uptake capacity. Thus, the reduction in DAT levels in
DAT  Ala mice is conceivably a consequence of disrupt-
ing the interaction between DAT and other yet unknown
PDZ-domain scaffolding proteins. Interestingly, despite
the reduction in functional DAT levels, we observe no
change in the acute locomotor response to cocaine in the
DAT  Ala mice (Fig. 4G). This supports the notion that
even rather large changes in DAT level do not necessarily
affect the acute actions of cocaine. This finding is consis-
tent with earlier studies using DAT heterozygous mice,
which have a 50% reduction in DAT, but are behaviorally
fully responsive to cocaine and amphetamine (Giros et al.,
1996; Jones et al., 1998, 1999). Homozygous DAT KO
mice, however, are behaviorally nonresponsive to co-
caine, consistent with DAT being the primary target for
cocaine (Giros et al., 1996; Jones et al., 1998, 1999). In
summary, we argue that the 30% reduction in DAT
function seen in PICK1 KO mice is unlikely to account for
the attenuated behavioral response to cocaine in these
mice.
To further explore mechanisms underlying the impaired
cocaine responses in PICK1 KO mice, we investigated
key parameters related to DA homeostasis. Levels of the
rate-limiting enzyme in DA synthesis, TH, were signifi-
cantly elevated in striatum of PICK1 KO mice (Fig. 5E),
suggesting increased DA synthesis capacity in this region.
There was no change, however, in midbrain TH levels and
no transcriptional change, which suggests that a role of
PICK1 in regulation of TH protein levels is selective to
mesostriatal projections. Of interest, differential regulation
of TH levels has been reported before; a differential re-
duction of TH was observed in DAT KO mice between the
somatodendritic compartment and the striatal terminals
(Jaber et al., 1999; Salvatore et al., 2016). The difference
in TH levels between striatum and ventral midbrain in
PICK1 KO mice could be related to either a trafficking
dysfunction or differential regulation of TH in neuronal
perikarya compared to striatal terminals. Despite un-
changed levels of Ser40 phosphorylated TH (Lindgren
et al., 2000), the increased striatal TH levels observed
here are indicative of increased DA synthesis capacity
and consistent with this, we found higher DA levels in
striatal homogenates from PICK1 KO mice compared to
wild-type littermates (Fig. 5A). Moreover, high-speed
chronoamperometric recordings in striatum of PICK1 KO
mice revealed increased DA release on KCl stimulation
(Fig. 5B,C), consistent with increased striatal DA in PICK1
KO mice, which most likely can be attributed to increased
synthesis and DA storage. Of interest, overexpression of
the VMAT2 enhances vesicular storage capacity for DA
and increases striatal tissue DA levels (Lohr et al., 2014).
In PICK1 KO mice, however, VMAT2 expression was
unaltered compared to wild type (Fig. 5D), and abnormal
VMAT2 expression can therefore not account for in-
creased striatal DA in these mice.
The ability of PICK1 to regulate TH levels is most likely
inherent to dopaminergic neurons. Indeed, we observed
PICK1 expression in TH-immunolabeled neurons in mid-
brain (Fig. 6A) in agreement with previous data (Torres
et al., 2001). Furthermore, we found that lentiviral shRNA-
mediated KD of PICK1 in isolated, cultured midbrain do-
paminergic neurons enhances TH expression (Fig. 6D–F),
providing strong evidence for a functional link between
PICK1 and TH. Importantly, elevated TH expression fol-
lowing acute PICK1 KD in dissociated dopaminergic neu-
continued
corresponding to the 11 most C-terminal residues in TH or unlabeled DAT13 corresponding to the 13 most C-terminal residues in DAT
(dotted line). C, Coimmunoprecipitation experiments from both midbrain and striatal preparations show lack of any direct interaction
between TH and PICK1. Left upper left panel, IP of TH from striatum shows no co-IP of PICK1 (n  3). Right upper panel, IP of TH
from midbrain shows no co-IP of PICK1 (n  3). Left lower panel, IP of PICK1 from striatum shows no co-IP of TH (n  1). Right lower
panel, IP of PICK1 from midbrain shows no co-IP of TH (n  1). D, Representative confocal images of postnatal midbrain cultures of
rat dopaminergic neurons, virus transduced with vectors containing the constructs for cytosolic GFP (left panel) or cytosolic GFP and
the endogenous PICK1 silencing RNA sh18 (right panel). Scale bar: 10 m. E, Significantly elevated TH expression in PICK1 KD versus
wild-type neurons (t(78) 2.68, p 0.009;127% compared to wild type). F, KD efficiency of the lentiviral PICK1 KD show significant
reduction of PICK1 (p  0.0001). All data expressed as mean  SEM.
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rons, where neurons are disconnected from synaptic
input, strongly argues that the observed TH increase in
PICK1 KO mice is not explained by compensatory pre- or
postsynaptic adaptations caused by the global KO of
PICK1. Based on these findings, it was obvious to sus-
pect a direct interaction between PICK1 and TH. How-
ever, the mouse TH C-terminus showed very poor affinity
for the PICK1 PDZ-domain (Fig. 6B). Moreover, coimmu-
noprecipitation experiments did not support any associ-
ation between PICK1 and TH (Fig. 6C). This suggests that
the exact manner by which PICK1 regulates TH remains
elusive. It might be speculated that this regulation de-
pends on the interaction of PICK1 with one of its other
binding partners, but future investigations are warranted
to address this issue.
In conclusion, we show that deletion of PICK1 markedly
impairs behavioral responses to cocaine. It is unlikely that
the impaired acute locomotor response to cocaine is
related to the interaction between PICK1 and DAT. This
deficit might rather be attributed to significant changes in
DA synthesis and release dynamics in striatal nerve ter-
minals. Indeed, the higher levels of resting DA levels in
concert with decreased DA uptake capacity implies that
the window of resting and saturation levels is limited,
which could be part of the explanation to the impaired
behavioral response to cocaine. Notably, increased tissue
levels of monoamines promoted by overexpression of
Drosophila VMAT in fly brain impair behavioral responses
to cocaine (Chang et al., 2006). We also observed re-
duced cocaine self-administration consistent with in-
volvement of PICK1 in regulation of neuroadaptive
changes occurring after repeated cocaine exposures. By
establishing PICK1 as a key player in psychostimulants
action, our data provide an important framework for ex-
ploring PICK1 as putative target for treatment of drug
abuse.
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